By Jill McKeon February 27, 2023 – The Department of Justice (DOJ) and the Federal Trade Commission (FTC) have officially resolved allegations against GoodRx surrounding violations of the FTC Act and the…
Continue Reading
Top News
Teladoc Health reports Q4 results: revenue up 15%, EPS –$0.23 versus –$0.07, beating revenue expectations but falling short on earnings.
The company reported a staggering $13.7 billion loss for FY 2022, much of…
Editor’s note: This story is based on an interview at Abarca Forward, a conference that was hosted by Abarca Health, a pharmacy benefit manager last week in San Juan, Puerto Rico. MedCity News’ Editor-in-Chief…
Continue Reading
Amazon closed its $3.9 billion acquisition of primary care provider One Medical shortly after multiple news outlets reported the Federal Trade Commission wouldn’t sue to block the deal.The acquisition marks another move into healthcare…
Continue Reading
The Federal Trade Commission has cited telehealth and prescription drug discount provider GoodRx for sharing sensitive consumer health data with several advertising platforms, in violation of its own privacy promises to consumers.
The agency has filed a proposed order demanding that GoodRx pay $1.5 million in civil penalties for failing to let consumers know about unauthorized disclosures of its data to a list of advertiser platforms. including Facebook and Google.
The company, which is based in California, operates a digital health platform offering prescription drug discounts, telehealth visits and other health services. It captures a wide range of data from consumers who use…
Primary care has been historically dominated by traditional providers that deliver care via fee-for-service models, but retail companies have been amping up their efforts to disrupt the space in recent years. Over the next decade, it will become increasingly difficult for hospitals and other traditional healthcare providers to ignore these disruptors, according to a recent report from the American Hospital Association.
The report cited a Bain & Company analysis that predicted disruptors could own as much as 30% of the $260 billion primary care market by 2030. So what moves by Amazon, Walmart and CVS will the industry need to watch to…
In this episode of Health+Tech, Andrea Lee Linna and Jonathan Ishee are joined by fellow McGuireWoods digital health team member Michael Paluzzi to discuss proposed HIPAA changes that may require covered entities and business associates to overhaul their HIPAA policies and procedures in 2022.After providing a high-level overview of the proposed changes, the podcast turns to a live recording of Andrea and Jonathan’s recent webinar, “Preparing for Major HIPAA Changes in 2022,” offering in-depth details about the proposed changes and how to prepare for them in the new year….
Continue Reading
In this episode of Health+Tech, McGuireWoods healthcare attorneys Janice Suchyta, Kate Hardey, Kae Gruner and Royce DuBiner discuss the latest digital health updates from the Food and Drug Administration and Federal Trade Commission. Join the conversation as we wrap up Cybersecurity Awareness Month and discuss the following topics:• FDA draft guidance on electronic health records and medical claims data• FDA new resource for approved artificial intelligence/machine learning medical devices• FDA Digital Health Center of Excellence• FTC rules for health apps outside of HIPAA…
Continue Reading
In this episode of Health+Tech, McGuireWoods healthcare partner Janice Suchyta talks to Michele Satterlund, senior vice president in the state government relations practice of McGuireWoods Consulting and a partner with McGuireWoods, on the emergence of telehealth, particularly during the pandemic. They also look at how telehealth is evaluated state by state and discuss the need for uniform best practices….
Continue Reading
In this episode of Health+Tech, McGuireWoods healthcare partner Janice M. Suchyta talks to Donna Chang, founder and CEO of Hope Biosciences. Donna discusses how Texas — particularly Houston — is making a name for itself in biotechnology by attracting research funding, supporting premier academic medical centers and welcoming investment by major pharmaceutical companies. Hope Biosciences, a stem cell biotechnology company that has flourished as part of the biotech cluster in the Houston area, is helping to make Texas the third coast for biotechnology….
Continue Reading
